Taysha Gene Therapies, Inc.
Clinical trials sponsored by Taysha Gene Therapies, Inc., explained in plain language.
Gene therapy company focused on rare monogenic diseases of the central nervous system.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Gene therapy hope for toddlers with rett syndrome
Disease control OngoingThis study tests a one-time gene therapy called TSHA-102 in girls aged 2 to 4 with Rett syndrome, a severe genetic disorder. The therapy is given as a single injection into the spine. The main goal is to check if it is safe and tolerable, and to see early signs of whether it help…
Phase 3 • Sponsor: Taysha Gene Therapies, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New gene therapy hopes to restore milestones in rett syndrome
Disease control OngoingThis study tests a one-time gene therapy called TSHA-102 in females aged 6 to under 22 with classic Rett syndrome. The goal is to see if it is safe and can help them regain or gain new developmental skills like walking or talking. Participants receive the therapy through a spinal…
Phase 3 • Sponsor: Taysha Gene Therapies, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Gene therapy hope for girls with rare brain disorder
Disease control OngoingThis study tests a new gene therapy called TSHA-102 for girls aged 5 to 8 with Rett syndrome, a severe genetic disorder that affects brain development. The therapy is given as a single injection into the spinal fluid. The main goal is to check safety and side effects, while also …
Phase 1/2 • Sponsor: Taysha Gene Therapies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC